Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess long term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome

X
Trial Profile

To assess long term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Dravet syndrome; Epilepsy; Generalised seizures; Lennox-Gastaut syndrome; Myoclonic epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms CBD EAP
  • Most Recent Events

    • 01 Dec 2023 According to a Jazz Pharmaceuticals Plc media release, data from this study will be presented at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida.
    • 29 Jul 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top